Home » Stocks » ETNB

89bio, Inc. (ETNB)

Stock Price: $21.10 USD 0.14 (0.64%)
Updated Jan 26, 2021 10:15 AM EST - Market open
Market Cap 416.66M
Revenue (ttm) n/a
Net Income (ttm) -56.20M
Shares Out 16.88M
EPS (ttm) -72.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $21.10
Previous Close $20.96
Change ($) 0.14
Change (%) 0.64%
Day's Open 21.00
Day's Range 20.81 - 21.13
Day's Volume 37,338
52-Week Range 16.40 - 41.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies...

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies...

GlobeNewsWire - 2 months ago

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –

GlobeNewsWire - 2 months ago

– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

GlobeNewsWire - 4 months ago

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo    

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/...

GlobeNewsWire - 4 months ago

- Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks - - Multi-center, rando...

GlobeNewsWire - 5 months ago

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 -

Zacks Investment Research - 5 months ago

89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 5 months ago

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other stocks mentioned: ARCT, AVRO, FULC, ICPT
GlobeNewsWire - 5 months ago

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

GlobeNewsWire - 6 months ago

SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

Zacks Investment Research - 6 months ago

89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

GlobeNewsWire - 8 months ago

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 -

GlobeNewsWire - 9 months ago

- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline ...

GlobeNewsWire - 10 months ago

SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

About ETNB

89bio, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Industry
Biotechnology
IPO Date
Nov 11, 2019
CEO
Rohan Palekar
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
ETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for 89bio stock is "Strong Buy." The 12-month stock price forecast is 59.88, which is an increase of 183.86% from the latest price.

Price Target
$59.88
(183.86% upside)
Analyst Consensus: Strong Buy